Search: onr:"swepub:oai:DiVA.org:uu-240064" >
Vorapaxar with or w...
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes : Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
-
Tricoci, Pierluigi (author)
-
Lokhnygina, Yuliya (author)
-
Huang, Zhen (author)
-
show more...
-
Van de Werf, Frans (author)
-
Cornel, Jan H. (author)
-
Chen, Edmond (author)
-
- Wallentin, Lars (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Kardiologi
-
- Held, Claes, 1956- (author)
- Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för medicinska vetenskaper
-
Aylward, Philip E. (author)
-
Moliterno, David J. (author)
-
Jennings, Lisa K. (author)
-
White, Harvey D. (author)
-
Armstrong, Paul W. (author)
-
Harrington, Robert A. (author)
-
Strony, John (author)
-
Mahaffey, Kenneth W. (author)
-
show less...
-
(creator_code:org_t)
- Elsevier BV, 2014
- 2014
- English.
-
In: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 168:6, s. 869-877.e1
- Related links:
-
https://urn.kb.se/re...
-
show more...
-
https://doi.org/10.1...
-
show less...
Abstract
Subject headings
Close
- Background Protease-activated receptor 1 antagonism with vorapaxar represents a novel strategy for platelet inhibition. In TRACER, vorapaxar was compared with placebo plus standard of care among 12,944 patients with non-ST-segment elevation acute coronary syndromes. We anticipated that most patients would have received clopidogrel as part of standard care. We investigated the modification of vorapaxar's effect associated with clopidogrel use over time. Methods The marginal structural model method was used to estimate causal modification of vorapaxar effect by use of clopidogrel over time. The primary outcomes were the composite of cardiovascular death, myocardial infarction, or stroke and Global Use of Strategies to Open Occluded Coronary Arteries moderate or severe bleeding. The event accrual period excluded the time during which clopidogrel was clinically warranted. Results Among 12,887 patients who received study medication, 11,117 (86.3%) received clopidogrel before randomization, of whom 38.5% stopped later in the trial (median time to stoppage 200 days with placebo; interquartile range [IQR] 14-367) (186 days with vorapaxar; IQR 17-366). In total, 1,770 (13.7%) patients were not on clopidogrel at randomization, of whom 47.8% started afterward (median time to start 2 days; IQR 2-4). During the period of event accrual, vorapaxar was associated with a 26% reduction in the composite of cardiovascular death, myocardial infarction, or stroke when used with clopidogrel (hazard ratio [HR] 0.74; 95% CI 0.60-0.91) and a 24% reduction when used without clopidogrel (HR 0.76; 95% CI 0.56-1.02) (interaction; P = .89). The hazard of Global Use of Strategies to Open Occluded Coronary Arteries bleeding with vorapaxar was not significantly different without clopidogrel (HR 1.33; 95% CI 0.81-2.20) or with clopidogrel (HR 1.09; 95% CI 0.76-1.56) (interaction; P = .53). Conclusions We observed no interaction between vorapaxar and clopidogrel after non-ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y(12) antagonism.
Subject headings
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
To the university's database
- By the author/editor
-
Tricoci, Pierlui ...
-
Lokhnygina, Yuli ...
-
Huang, Zhen
-
Van de Werf, Fra ...
-
Cornel, Jan H.
-
Chen, Edmond
-
show more...
-
Wallentin, Lars
-
Held, Claes, 195 ...
-
Aylward, Philip ...
-
Moliterno, David ...
-
Jennings, Lisa K ...
-
White, Harvey D.
-
Armstrong, Paul ...
-
Harrington, Robe ...
-
Strony, John
-
Mahaffey, Kennet ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cardiac and Card ...
- Articles in the publication
-
American Heart J ...
- By the university
-
Uppsala University